Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Randomized Study of TLK286 (Telcyta) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5).

Next Previous
Search
Trial Profile

Phase 3 Randomized Study of TLK286 (Telcyta) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canfosfamide (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ASSIST-5
  • Sponsors Telik

Most Recent Events

  • 23 Feb 2011 Primary endpoint 'Progression-free-survival' has not been met according to article in the International Journal of Gynecological Cancer.
  • 02 Jun 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
  • 02 Jun 2009 Results were reported at ASCO 2009.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top